Q2 2023 Earnings Estimate for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Issued By Wedbush

Posted by Defense World Staff on May 22nd, 2023

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Rating) – Equities research analysts at Wedbush raised their Q2 2023 earnings estimates for shares of ARS Pharmaceuticals in a report issued on Thursday, May 18th. Wedbush analyst A. Argyrides now expects that the company will post earnings per share of ($0.19) for the quarter, up from their prior estimate of ($0.20). Wedbush currently has a “Outperform” rating and a $10.00 target price on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.75) per share. Wedbush also issued estimates for ARS Pharmaceuticals’ Q3 2023 earnings at ($0.16) EPS, Q4 2023 earnings at ($0.14) EPS, FY2023 earnings at ($0.65) EPS, FY2024 earnings at ($0.67) EPS, FY2025 earnings at ($0.48) EPS, FY2026 earnings at ($0.20) EPS and FY2027 earnings at $0.15 EPS.

ARS Pharmaceuticals Price Performance

NASDAQ:SPRY opened at $8.57 on Monday. The business has a 50-day simple moving average of $6.81. ARS Pharmaceuticals has a 12-month low of $3.12 and a 12-month high of $9.65.

Insider Buying and Selling

In other news, Director Laura Shawver sold 42,900 shares of the company’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $5.31, for a total value of $227,799.00. Following the sale, the director now owns 210,346 shares of the company’s stock, valued at approximately $1,116,937.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 34.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC bought a new position in ARS Pharmaceuticals in the 1st quarter valued at $84,000. State Street Corp increased its stake in shares of ARS Pharmaceuticals by 50.4% in the first quarter. State Street Corp now owns 129,191 shares of the company’s stock valued at $841,000 after buying an additional 43,300 shares in the last quarter. Jane Street Group LLC bought a new stake in ARS Pharmaceuticals during the 1st quarter worth about $895,000. Geode Capital Management LLC acquired a new stake in ARS Pharmaceuticals in the 1st quarter valued at about $2,627,000. Finally, Baker BROS. Advisors LP bought a new position in shares of ARS Pharmaceuticals in the first quarter worth about $13,062,000.

ARS Pharmaceuticals Company Profile

(Get Rating)

ARS Pharmaceuticals, Inc develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.